IU research points to a biomarker for cardiotoxicity in breast cancer–and a role for dexamethasone

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An Indiana University School of Medicine study produced a potential biomarker for chemotherapy-induced cardiotoxicity in breast cancer patients. The researchers also identified a drug that may work to minimize cardiotoxicity.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login